USC removes name of Rufus von KleinSmid, a eugenics leader, from prominent building
By Teresa Watanabe and Tomás Mier,
Los Angeles Times
| 06. 12. 2020
The scholar, who is credited with expanding the university’s academic programs and international relations curriculum as president from 1921 to 1947, believed that people with “defects” had no ethical right to parenthood and should be sterilized.
With its soaring arches, international flags and globe-topped tower, the Von KleinSmid Center for International and Public Affairs is one of the most prominent buildings at USC. Its namesake, the late Rufus B. von KleinSmid, has held a place of distinction as the university’s fifth president.
But on Thursday, USC announced it had stripped Von KleinSmid’s name from the building as the university at last reconciled with his disturbing leadership role in California’s eugenics movement.
The scholar, who is credited with expanding the university’s academic programs and international relations curriculum as president from 1921 to 1947, believed that people with “defects” had no ethical right to parenthood and should be sterilized. His “Human Betterment Foundation” was instrumental in supporting the 1909 California legislation that authorized the forced sterilization of those deemed “unfit” — essentially anyone non-white, said Alexandra Minna Stern, a University of Michigan history professor and expert on eugenics.
His active support of eugenics is “at direct odds with USC’s multicultural community and our mission of diversity and inclusion,” President Carol L. Folt announced.
“This moment is our Call...
Related Articles
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first...
By Walt Bogdanich and Carson Kessler, The New York Times | 10.23.2024
By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401. For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease...
By Ashleigh Wyss [cites CGS' Katie Hasson], Listnr | 10.09.2024
Discovering your genetic history can be as simple as spitting into a test tube, but what happens when your data ends up in the wrong hands?
With at-home DNA test kits becoming increasingly popular throughout the 2010s, curious consumers have...
By Kevin Davies , Genetic Engineering and Biotechnology News | 10.22.2024
